Osimertinib-Associated Cardiomyopathy In Patients With Non-Small Cell Lung Cancer: A Case Series

Related Experiment Video

Updated: Jul 5, 2025

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.0K

Miguel J Franquiz, Sarah Waliany, Audrey Yingwei Xu

    JACC. Cardiooncology
    |January 11, 2024
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
    08:52

    Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

    Published on: November 22, 2021

    4.0K
    Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
    09:38

    Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

    Published on: August 11, 2017

    8.8K

    Related Experiment Videos

    Last Updated: Jul 5, 2025

    Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
    09:38

    Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

    Published on: June 26, 2019

    8.0K
    Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
    08:52

    Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

    Published on: November 22, 2021

    4.0K
    Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
    09:38

    Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

    Published on: August 11, 2017

    8.8K

    Related Concept Videos

    Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

    Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

    167
    Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
    TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
    167
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    7.6K
    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    7.6K

    Articles linked to this work by shared authors, journal, and citation graph.

    Aptamer-mediated multivalent endogenous ADAR1 recruitment for highly efficient RNA editing.

    Nature methods·2026

    Impact of hearing loss on visual selective attention: Evidence from N2pc and resting-state networks.

    NeuroImage·2026

    Beyond a Single Continuum: Latent Profiles of Flourishing and Burnout Among Chinese Teachers.

    Behavioral sciences (Basel, Switzerland)·2026

    Attention Networks in Deaf Youth: A Cross-Sectional Study of Age-Related Patterns.

    Journal of Intelligence·2026

    Immune Responses in Checkpoint Inhibitor-Associated Cardiovascular Immune-Related Adverse Events: JACC: CardioOncology State-of-the-Art Review.

    JACC. CardioOncology·2026

    When bioactivity comes at a mechanical cost: toward mechanically safe bioactivation of zirconia dental implants.

    Bioactive materials·2026

    High-Sensitivity Cardiac Troponin T and I Discordance in Patients Receiving Immune Checkpoint Inhibitors.

    JACC. CardioOncology·2026

    Fibrotic Rewiring of CD8+ T Cells by Doxorubicin Drives Pathological Remodeling of Cardiac Extracellular Matrix.

    JACC. CardioOncology·2026

    Management and Surveillance of Immune Checkpoint Inhibitor Myocarditis: Managing the Aftermath: JACC CardioOncology State-of-the-Art Review.

    JACC. CardioOncology·2026

    Association of Life's Essential 8 With Clonal Hematopoiesis and Coronary Artery Disease.

    JACC. CardioOncology·2026

    Real-World Cardiotoxicity of Biosimilar versus Reference Trastuzumab in Early HER2-Positive Breast Cancer.

    JACC. CardioOncology·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us